3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
33
Thoracic
4
Plasma cell
3
Genitourinary
2
Gastrointestinal
2
CNS
2
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Prostatic Neoplasms
1641
Carcinoma, Renal Cell
504
Urinary Bladder Neoplasms
462
Carcinoma, Transitional Cell
234
Breast Neoplasms
228
Kidney Neoplasms
217
Neoplasms
194
Carcinoma, Non-Small-Cell Lung
173
Colorectal Neoplasms
172
Ovarian Neoplasms
163
Melanoma
162
Neoplasm Metastasis
143
Lung Neoplasms
128
Non-Muscle Invasive Bladder Neoplasms
107
Pancreatic Neoplasms
103
Stomach Neoplasms
101
Uterine Cervical Neoplasms
93
Squamous Cell Carcinoma of Head and Neck
86
Endometrial Neoplasms
84
Carcinoma, Hepatocellular
77
Sarcoma
75
Esophageal Neoplasms
72
Head and Neck Neoplasms
70
Triple Negative Breast Neoplasms
67
Adenocarcinoma
66
Colonic Neoplasms
53
Testicular Neoplasms
52
Disease
47
Urologic Neoplasms
46
Wilms Tumor
45
Interventions
Rivaroxaban
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Venous Thromboembolism
×
Genitourinary
×
1 year
×
Clear all
NCT06866964
2026-02-02
ASPIRE
Wake Forest University Health Sciences
Phase 2
Recruiting
35 enrolled
NCT05920343
2025-07-10
PREVENT-GU
Ottawa Hospital Research Institute
Phase 2/3
Recruiting
120 enrolled